MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Pfizer DPO Ratio 2011-2026 | PFE
Annual DPO Ratio Pfizer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124 | 126 | 98.9 | 65.8 | 58.5 | 183 | 151 | 152 | 151 | 134 | 137 | 131 | 123 | 137 | 92.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 183 | 58.5 | 124 |
Quarterly DPO Ratio Pfizer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 | 126 | 169 | 90.3 | 148 | 148 | 56.2 | 172 | 121 | - | 93.9 | 61.8 | 50.6 | - | 41.5 | 54.7 | 91.6 | - | 196 | 215 | 193 | - | 148 | 149 | 167 | - | 158 | 146 | 166 | - | 149 | 160 | - | - | - | - | - | - | - | - | - | - | - | - | 144 | - | 129 | 132 | 124 | - | 115 | 138 | 132 | - | 98.5 | 90.1 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 215 | 41.5 | 128 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K |  USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Amarin Corporation plc
AMRN
|
190 | $ 14.67 | -0.07 % | $ 6.09 B |  Irlanda |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 1.09 | -9.17 % | $ 22.4 M | Israel |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 2.85 | 3.26 % | $ 592 M | USA |
 |
Eton Pharmaceuticals
ETON
|
74.3 | $ 23.45 | -1.64 % | $ 631 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
324 | $ 1.32 | -5.2 % | $ 1.88 M | China |
 |
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.45 | -1.77 % | $ 853 M | Canada |